Letter: Clinical Prognostic Factors and Molecular Characteristics of Spinal Cord Diffuse Midline Gliomas

To the Editor: We read with great interest the article by Gao et al,1 titled “Clinical Prognostic Factors and Molecular Characteristics of Spinal Cord Diffuse Midline Gliomas,” which presents a comprehensive clinical and molecular analysis of 46 patients with spinal cord diffuse midline gliomas (DMGs). The authors examined a rare but highly aggressive tumor subtype using rigorous statistical methodology and succeeded in uncovering several underappreciated clinical insights—particularly in relation to surgical resection and histological grading. This work is highly valuable in multiple dimensions. First, it challenges the oversimplified principle embedded in the 2021 WHO classification, which uniformly categorizes all H3 K27-altered DMGs as WHO grade IV, regardless of histopathological variation.2 The authors' findings that histological grade II and III tumors demonstrated significantly better survival compared with grade IV tumors call for a more nuanced, individualized approach to risk stratification and treatment planning for spinal cord DMG. Second, the study highlighted that thoracic and thoracolumbar tumor locations, along with gross total resection, were significantly associated with improved outcomes—particularly in lower-grade tumors. These observations suggest that early and aggressive surgical intervention may yield meaningful survival benefits in select patients.3,4 Such findings are not only clinically relevant but also critical for neurosurgical decision-making, especially considering the limited efficacy of standard chemoradiation in DMG. Nonetheless, several areas merit further discussion. The absence of functional outcome data, such as postoperative neurological scores or quality-of-life assessments, limits the ability to fully evaluate the impact of surgical aggressiveness. Moreover, a more granular analysis of adjuvant treatment strategies and their differential effects across tumor grades would have added significant depth. In addition, imaging characteristics—often correlated with invasiveness and resectability—were underrepresented in the study's analysis. Future multicenter, prospective investigations are warranted to validate these findings, integrate radiological phenotypes, and further elucidate the molecular mechanisms driving prognosis in spinal cord DMG. Despite these limitations, the work by Gao et al marks a significant step forward in redefining and managing spinal DMG beyond molecular classification alone. It not only challenges conventional paradigms but also establishes a thoughtful framework for personalized therapeutic strategies in rare spinal tumors. This study demonstrates both scientific rigor and clinical foresight, and it offers an exemplary model for future research in the field.